Yutaka Eguchi
Overview
Explore the profile of Yutaka Eguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Itagaki Y, Hayakawa M, Takahashi Y, Sakamoto Y, Kushimoto S, Eguchi Y, et al.
JMIR Res Protoc
. 2023 Dec;
12:e49582.
PMID: 38079205
Background: Trauma-induced coagulopathy (TIC) is a common and potentially life-threatening coagulopathy as a result of traumatic injury, characterized by abnormal blood clotting and bleeding. Although several treatments have been proposed...
2.
Mori K, Tsujita Y, Yamane T, Eguchi Y
Clin Appl Thromb Hemost
. 2022 May;
28:10760296221101386.
PMID: 35549920
Plasma fibrinogen levels increase in response to infection, but they could also decrease due to degradation as in severe coagulopathy. We evaluated 60 septic patients with their CRP levels over...
3.
Murao A, Kato T, Yamane T, Honda G, Eguchi Y
Clin Appl Thromb Hemost
. 2022 Feb;
28:10760296221077096.
PMID: 35166576
Thrombomodulin alfa (TM-α, recombinant human soluble thrombomodulin) and antithrombin (AT) concentrate are anticoagulant agents for the treatment of disseminated intravascular coagulation (DIC). A post hoc analysis using data from 1198...
4.
Mizuno T, Eguchi Y, Tsujita Y, Imashuku Y, Tabata T, Kitagawa H
Acute Med Surg
. 2022 Feb;
9(1):e726.
PMID: 35127103
Aim: High mobility group box-1 (HMGB1) is a lethal mediator of sepsis that binds to haptoglobin (Hp) and is associated with its prognosis. We investigated the effect of the combination...
5.
Abe T, Matsuo H, Abe R, Abe S, Asada H, Ashida A, et al.
Ther Apher Dial
. 2021 Dec;
25(6):728-876.
PMID: 34877777
Most of the diseases for which apheresis therapy is indicated are intractable and rare, and each patient has a different background and treatment course prior to apheresis therapy initiation. Therefore,...
6.
Katagi M, Terashima T, Ohashi N, Nakae Y, Yamada A, Nakagawa T, et al.
Commun Biol
. 2021 May;
4(1):575.
PMID: 33990693
Diabetic neuropathy is an incurable disease. We previously identified a mechanism by which aberrant bone marrow-derived cells (BMDCs) pathologically expressing proinsulin/TNF-α fuse with residential neurons to impair neuronal function. Here,...
7.
Miyatake H, Asada K, Tabata T, Eguchi Y, Matsutani N, Nakagawa Y
Circ J
. 2021 Feb;
85(4):400.
PMID: 33583870
No abstract available.
8.
Miyatake H, Tabata T, Tsujita Y, Fujino K, Tanaka R, Eguchi Y
Circ J
. 2021 Feb;
85(4):361-368.
PMID: 33583868
Background: Recently, dynamic chest radiography (DCR) was developed to evaluate pulmonary function using a flat-panel detector (FPD), which can evaluate blood flow in the pulmonary artery without injection of contrast...
9.
Kato T, Fujino K, Tsujita Y, Miyatake H, Tabata T, Eguchi Y
Acute Med Surg
. 2021 Feb;
8(1):e630.
PMID: 33532079
Aim: We aimed to investigate the association between aortic calcification and 90-day mortality in sepsis patients admitted to the intensive care unit. Methods: We evaluated adult patients (≥18 years) diagnosed...
10.
Shimizu J, Fujino K, Sawai T, Tsujita Y, Tabata T, Eguchi Y
Acute Med Surg
. 2021 Jan;
8(1):e625.
PMID: 33510899
Aim: The complement system is important for defending against pathogens, however, excessive complement activation is associated with a poor prognosis and organ dysfunction in sepsis. Complement factor H (CFH) acts...